Milestones :: Perspectives :: Research

COVID Vaccine Developer Announcements

Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population
Phase 2/3 study expected to enroll 6,750 healthy pediatric participants less than 12 years of age
March 16, 2021

First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine
mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers
March 15, 2021

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Takeda will make manufacturing capacity available at IDT’s facilities in Germany
March 15, 2021
… With this agreement, Takeda is now supporting global access to three different COVID-19 vaccines. Takeda previously announced its commitment to providing rapid and sustained access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna…